Amphista
Cambridge, GB · 8 known investors
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins. The company designs degraders that combine favorable properties of PROTAC and molecular glue approaches to address a wider range of tissues and disease indications.
Founders & leadership
Investors · 8
Advent Life SciencesLondon
Novartis Venture FundBasel · $5M – $25M
SV Health InvestorsBoston · $1M – $20M
Dementia Discovery Fundreported · 2 sourcesLondon
European Investment FundreportedLuxembourg
ForbionreportedNaarden
Gilde HealthcarereportedUtrecht · $1.1M – $55M
Scottish Investment BankreportedGlasgow · $250K – $2M
In the news
Frequently asked questions
- What does Amphista do?
- Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins. The company designs degraders that combine favorable properties of PROTAC and molecular glue approaches to address a wider range of tissues and disease indications.
- Who are Amphista's investors?
- Amphista's investors include Advent Life Sciences, Novartis Venture Fund, SV Health Investors, Dementia Discovery Fund, European Investment Fund, Forbion, Gilde Healthcare, Scottish Investment Bank.
- Where is Amphista headquartered?
- Amphista is headquartered in Cambridge, GB.